Total (n=159) Patients with KMP (n=64) Patients without KMP (n=95) p-value
Systemic Therapy Given, n (%) 136 (85.5%) 61 (95.3%) 75 (79.0%) 0.005
Primary Treatment Category, n (%) Sirolimus Vincristine Siro+VCR Steroids Minimal Surgery/IR 51 (32.1%) 25 (15.7%) 7 (4.4%) 32 (20.1%) 27 (17.0%) 17 (10.7%) 19 (29.7%) 16 (25.0%) 7 (10.9%) 16 (25.0%) 2 (3.1%) 4 (6.3%) 32 (33.7%) 9 (9.5%) 0 (0%) 16 (16.8%) 25 (26.3%) 13 (13.7%)
Time Between Initial Symptoms and Treatment Initiation (days), median [IQR] 52.0 [9.5, 235.5] 16.0 [3.0, 44.0] 179.0 [64.5, 456.0] <0.001
Time Between Diagnosis and Treatment Initiation (days), median [IQR] 9.0 [1.0, 52.8] 3.0 [1.0, 10.0] 21.0 [6.0, 71.0] <0.001
Received Blood Product Transfusions, n (%) 56 (35.2%) 50 (78.1%) 6 (6.3%) <0.001
Received Opioid Medication, n (%) 33 (20.8%) 19 (29.7%) 14 (14.7%) 0.028
Interventional Radiology Procedure Attempted, n (%) 16 (10.1%) 8 (12.5%) 8 (8.4%) 0.2
Surgical Resection Attempted, n (%) 28 (17.6%) 8 (12.5%) 20 (21.1%) 0.2
Reason for Treatment Initiation, n (%) Coagulopathy Thrombocytopenia Anemia Pain Recurrent cellulitis Visceral or bone involvement Cardiac dysfunction Airway compression Limb dysfunction Cosmetic look Extent of disease 65 (40.9%) 59 (37.1%) 22 (13.8%) 61 (38.4%) 2 (1.3%) 12 (7.5%) 5 (3.1%) 11 (6.9%) 29 (18.2%) 34 (21.4%) 87 (54.7%) 51 (79.7%) 53 (82.8%) 21 (32.8%) 18 (28.1%) 1 (1.6%) 6 (9.4%) 5 (7.8%) 10 (15.6%) 9 (14.1%) 7 (10.9%) 40 (62.5%) 14 (14.7%) 6 (6.3%) 1 (1.1%) 43 (45.3%) 1 (1.1%) 6 (6.3%) 0 (0%) 1 (1.1%) 20 (21.1%) 27 (28.4%) 47 (49.5%) <0.001 <0.001 <0.001 0.032 >0.9 0.5 0.010 <0.001 0.3 0.010 0.14